Venetoclax with Hypomethylating agents in newly diagnosed Acute myeloid leukemia: a systematic review and Meta-analysis of Survival Data from Real-World …
A Ucciero, F Pagnoni, L Scotti, A Pisterna… - Cancers, 2023 - mdpi.com
Simple Summary The association of venetoclax (VEN) with hypomethylating agents (HMAs)
such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of …
such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of …
[HTML][HTML] Venetoclax in adult acute myeloid leukemia
M Hu, W Li, Y Zhang, C Liang, J Tan, Y Wang - Biomedicine & …, 2023 - Elsevier
Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which
has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia …
has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia …
Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A …
Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes
(MDS) is difficult in older patients with comorbidities and high-risk disease factors …
(MDS) is difficult in older patients with comorbidities and high-risk disease factors …
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from …
Y Abaza, ES Winer, GSG Murthy… - American journal of …, 2024 - Wiley Online Library
Venetoclax (VEN) combined with hypomethylating agents (HMAs) is the standard of care for
the treatment of patients with newly diagnosed acute myeloid leukemia (AML) unfit for …
the treatment of patients with newly diagnosed acute myeloid leukemia (AML) unfit for …
Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data
FW Hoff, PA Patel, AJ Belli, E Hansen… - Leukemia & …, 2023 - Taylor & Francis
Venetoclax (VEN) in combination with hypomethylating agents (HMA) or low-dose
cytarabine has become the standard of care for patients with acute myeloid leukemia (AML) …
cytarabine has become the standard of care for patients with acute myeloid leukemia (AML) …
[HTML][HTML] Early real-world first-line treatment with venetoclax plus hmas versus hma monotherapy among patients with aml in a predominately us community setting
Background Venetoclax in combination with hypomethylating agents (HMAs) is standard-of-
care in patients with newly diagnosed acute myeloid leukemia (AML) who are≥ 75 years …
care in patients with newly diagnosed acute myeloid leukemia (AML) who are≥ 75 years …
Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience
C Li, CX Deng, P Wu, KF Liu, X Huang… - Clinical and …, 2024 - Wiley Online Library
Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge.
We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of …
We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of …
Post‐remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre‐versus post‐VIALE‐A real …
P Vachhani, E Ma, T Xu, M Montez, S Worth… - Cancer …, 2023 - Wiley Online Library
Background This retrospective cohort study used an electronic health record‐derived, de‐
identified, US patient‐level database to better understand the real‐world treatment …
identified, US patient‐level database to better understand the real‐world treatment …
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
J Marvin‐Peek, JS Gilbert, DA Pollyea… - American journal of …, 2024 - Wiley Online Library
The advent of molecularly targeted therapeutics has transformed the management of
patients with acute myeloid leukemia (AML). Particularly for individuals unfit for intensive …
patients with acute myeloid leukemia (AML). Particularly for individuals unfit for intensive …
Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
J Cui, X Chen, C Li, Q Yan, G Yuan - Hematology, 2024 - Taylor & Francis
ABSTRACT Objectives The combination of Venetoclax (VEN) and Azacitidine (AZA)
increases survival outcomes and yields excellent responses in patients with acute myeloid …
increases survival outcomes and yields excellent responses in patients with acute myeloid …